PPARG and cystic fibrosis: Pioglitazone and rosiglitazone are known to activate peroxisome proliferator-activated receptor gamma (PPARγ) and it has been suggested that a reversible defect in PPARγ signaling in Cftr-deficient cells could improve the severity of the CF phenotype in mice.